- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01389479
Study to Evaluate the Safety, Tolerance and Immunogenicity of Fluviral™ in Healthy Adults
June 7, 2017 updated by: GlaxoSmithKline
Active-control Study to Evaluate the Safety, Tolerance and Immunogenicity of Fluviral™ S/F Influenza Vaccine in Healthy Adults Aged 18-64 Years of Age
The purpose of the study is to evaluate the safety, tolerance and immunogenicity of Fluviral™ in healthy adults aged 18-64 years.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study was conducted by ID BioMedical which has been taken over by GlaxoSmithKline.
At the time of conduct of this study, Fluviral was produced by ID BioMedical.
Study Type
Interventional
Enrollment (Actual)
1000
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 64 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female.
- Adults 18-64 years of age, inclusive.
- Satisfactory baseline medical assessment by history, physical examination, and clinical laboratory testing.
- Capable of informed consent.
- Able, willing and likely to fully comply with study procedures and restrictions.
Exclusion Criteria:
- Acute illness at the time of enrollment.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus infection and/or chronic use of immunosuppressants of other immune-modifying drugs within 6 months of administration of the study vaccine.
- Presence of an unstable chronic illness.
- Complicated diabetes mellitus.
- Active neurological disorder.
- History of any demyelinating disease including Guillain-Barré syndrome.
- Any clinical laboratory abnormality.
- Any disorder of coagulation or treatment with coumadin derivatives or heparin.
- Vital sign abnormalities at screening.
- Acute or chronic liver, renal or inflammatory bowel disease or collagen vascular disease.
- Cancer, or treatment for cancer, within three years.
- History of significant alcohol or drug abuse within one year prior to the screening visit.
- Positive urine drug screen at screening within 3 months prior to the screening visit or hard drugs. Products such as ativan, tylenol with codeine should be stopped sufficiently ahead of the screening visit in order to avoid a positive urine drug screen.
- Positive testing for hepatitis B, hepatitis C or human immunodeficiency virus at screening.
- Receipt of an influenza vaccine within 9 months prior to dosing.
- Planned administration of any other vaccines 30 days before study immunization or during the course of the study. Immunization on an emergency basis, such as Tetanus and Diphtheria Toxoids Adsorbed for adult use, will be allowed provided the vaccine is not administered within two weeks prior to study immunization.
- Use of any investigational or non-registered drug or vaccine or participation in an investigational study within 30 days prior to administration of study vaccine, or planned use during the study period.
- Receipt of any immunoglobulins and/or any blood products within three months of screening or planned administration of any of these products during the study period.
- Receipt of a depot injection or an implant of any drug within 3 months prior to administration of study vaccine.
- Any known or suspected allergy to any constituent of Fluviral™ S/F or Fluzone®.
- A history of severe adverse reaction to a previous dose of any influenza vaccine.
- History of anaphylactic type reactions to consumption of eggs.
- Any other condition or social circumstance that, in the opinion of the Principal Investigator, would make the subject unsuitable for or unable to complete the study.
- Breast-feeding subject.
- Positive urine pregnancy test at screening.
- Female subjects having sexual intercourse with any non-sterile male partner within 14 days prior to vaccine administration and without a history of acceptable contraception.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fluviral Group
|
Intramuscular, single dose
|
Active Comparator: Fluzone Group
|
Intramuscular, single dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of subjects with solicited local and systemic reactogenicity symptoms
Time Frame: First three days after vaccination
|
First three days after vaccination
|
Number of subjects reporting spontaneous adverse events
Time Frame: Throughout the entire study period (Day 0-42)
|
Throughout the entire study period (Day 0-42)
|
Immune response in terms of number of seroconverted subjects
Time Frame: Before (Day 0) and after (Day 21) vaccination
|
Before (Day 0) and after (Day 21) vaccination
|
Immune response in terms of number of seroprotected subjects
Time Frame: Before (Day 0) and after (Day 21) vaccination
|
Before (Day 0) and after (Day 21) vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunogenicity with respect to components of the study vaccine in terms of number of subjects with titres above the pre-defined cut-off
Time Frame: At Day 21 after vaccination
|
Titres calculated as geometric mean
|
At Day 21 after vaccination
|
Immune response to components of the study vaccine in terms of mean Geometric increase
Time Frame: At Day 21 after vaccination
|
At Day 21 after vaccination
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2005
Primary Completion (Actual)
May 1, 2005
Study Completion (Actual)
May 1, 2005
Study Registration Dates
First Submitted
July 4, 2011
First Submitted That Met QC Criteria
July 6, 2011
First Posted (Estimate)
July 8, 2011
Study Record Updates
Last Update Posted (Actual)
June 8, 2017
Last Update Submitted That Met QC Criteria
June 7, 2017
Last Verified
May 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IDB-707-105
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
Gamaleya Research Institute of Epidemiology and...CompletedInfluenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1Russian Federation
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Avian Influenza | H1N1 InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...University of Oxford; Wellcome Trust; World Health OrganizationCompletedInfluenza | Avian Influenza | Severe InfluenzaSingapore, Thailand, Vietnam
-
NPO PetrovaxCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Acute Respiratory Infection | Influenza Type B | Flu | Influenza A H3N2 | Influenza A H1N1 | Flu, Human | Influenza EpidemicRussian Federation
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Influenza Immunisation | Avian InfluenzaUnited States
Clinical Trials on Fluviral™
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedInfluenza VaccinesCanada
-
GlaxoSmithKlineCompleted
-
brian.wardMedTeq; MEDICAL INTERNATIONAL TECHNOLOGIES (MIT CANADA) INC.Completed
-
University of British ColumbiaWithdrawn
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
Ottawa Hospital Research InstituteOntario HIV Treatment Network; Public Health Agency of Canada (PHAC); CIHR Canadian...Completed